- Our Company
- Patients & Families
- R & D
- Press Releases
- Rights Issue / Företrädesemission 2020
- The Share
- Financial Reports
- Financial Calendar
- Corporate governance
- Certified Adviser
- IR Contact
- Events and Presentations
Welcome to Alzinova AB’s IR pages.
Alzinova AB is a company specializing in the treatment of Alzheimer’s disease – one of our major health scourges, without effective treatment options.
Latest press releases
- 2020-11-16 | Regulatory Last day of trading in paid subscription units (Sw.BTU) and first day of trading for TO2 2020/2022
- 2020-11-04 | Regulatory Alzinova AB announces the study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 at a scientific congress.
Events & presentations
- 2020-11-04 Study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 presented at Clinical Trials in Alzheimer’s Disease (CTAD) 2020
- 2020-10-15 Redeye Neurology Seminar CNS, October 15, 2020 - webcast presentation (in Swedish)